Who Paid My Doc
Michael Simoff
Pulmonary Disease Detroit, MI Medical Doctor
NPI 1811065345 CMS profile 443634
Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202
General payments
$148,837
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$71,098
Through program year 2023, Michael Simoff of Detroit, MI is reported in the CMS Open Payments database as having received $148,837 across 147 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $71,098 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $581 | 10 | |
| 2022 | General | $13,644 | 19 | |
| 2021 | General | $38,043 | 45 | |
| 2020 | General | $44,234 | 26 | |
| 2019 | General | $52,335 | 47 |
Beside peers
- Michael Simoff
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to Michael Simoff were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | Michael Simoff | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $52,335 | $377 | $109–$1,340 | $163 |
| 2020 | $44,234 | $230 | $56–$907 | $114 |
| 2021 | $38,043 | $269 | $68–$1,072 | $132 |
| 2022 | $13,644 | $390 | $100–$1,457 | $149 |
| 2023 | $581 | $419 | $114–$1,659 | $160 |
| 2024 | $0 | $476 | $123–$1,818 | $164 |
| 2025 | $0 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 16 billing codesPaid by Medicare
$1,969
Medicare patients
11
Services billed
24
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Alzheimer's or dementia | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
147 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in Michigan
Related records
Pulmonary Disease in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.